Detection of chronic kidney disease with creatinine, cystatin c, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality

JAMA

Volumn 305, Issue 15, 2011, Pages 1545-1552

  Peralta, Carmen A ^a,b   Shlipak, Michael G ^a,b   Judd, Suzanne ^c   Cushman, Mary ^e   McClellan, William ^f   Zakai, Neil A ^e   Safford, Monika M ^d   Zhang, Xiao ^c   Muntner, Paul ^c   Warnock, David ^d  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; BIOLOGICAL MARKER;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GEOGRAPHY; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; ALBUMINURIA; BLOOD; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; FORECASTING; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK; URINE;

AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOLOGICAL MARKERS; CAUSE OF DEATH; CREATININE; CYSTATIN C; DISEASE PROGRESSION; FEMALE; FORECASTING; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK;

EID: 79955009821     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.468     Document Type: Article

References (33)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.AmJ Kidney Dis. 2002; 39(2)(suppl 1):S1-S266.
2. den Hartog JR, Reese PP, Cizman B, Feldman HI. The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin JAmSoc Nephrol. 2009;4(2):419-427.
3. Molitch ME, DeFronzo RA, FranzMJ, et al; American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79-S83.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl JMed. 2004;351(13):1296-1305.
5. Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73(11):1310-1315. (Pubitemid 351693160)
6. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354 (23):2473-2483. (Pubitemid 43855050)
7. Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749-2757. (Pubitemid 47531202)
8. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22(1): 147-155.
9. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
10. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5):1069-1077.
11. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
12. Levey AS, de Jong PE, Coresh J, et al. The definition, classification and prognosis of chronic kidney disease: A KDIGO Controversies Conference report [published online ahead of print December 8]. Kidney Int. doi:10.1038/ki.2010. 483.
13. Shlipak MG, Sarnak M, Katz R, et al. Cystatin-C and risk for mortality and cardiovascular disease in elderly adults. N Engl J Med. 2005;352:2049-2060. (Pubitemid 40664306)
14. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237-246. (Pubitemid 46768607)
15. Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: Time for a course correction. J Am Soc Nephrol. 2008;19(5):844-846.
16. Couser WG. Chronic kidney disease the promise and the perils. J Am Soc Nephrol. 2007;18(11): 2803-2805. (Pubitemid 350058384)
17. de Jong PE, Gansevoort RT. Fact or fiction of the epidemic of chronic kidney disease-let us not squabble about estimated GFR only, but also focus on albuminuria. Nephrol Dial Transplant. 2008;23 (4):1092-1095. (Pubitemid 351767532)
18. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: Applications and implications. Am J Kidney Dis. 2009;53(3)(suppl 3):S4-S16.
19. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: Objectives and design. Neuroepidemiology. 2005;25(3):135-143. (Pubitemid 41207066)
20. McClellan W, Speckman R, McClure L, et al. Prevalence and characteristics of a family history of endstage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol. 2007;18(4):1344-1352. (Pubitemid 46536922)
21. Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2008; 52(2):227-234. (Pubitemid 351978145)
22. 2. Am J Kidney Dis. 2010;56(3):486-495.
23. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51 (3):395-406. (Pubitemid 351273480)
24. Warnock DG, Muntner P, McCullough PA, et al; REGARDS Investigators. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis. 2010;56(5):861-871.
25. Matsushita K, van der Velde M, Astor BC, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
26. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2): 157-172. (Pubitemid 351193639)
27. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11-21.
28. Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: A cohort study. Ann Intern Med. 2011;154(1):12-21.
29. Foley RN, Wang C, Snyder JJ, Collins AJ, Cystatin C. Levels in U.S. Adults, 1988-1994 Versus 1999-2002: NHANES. Clin J Am Soc Nephrol. 2009;4(5):965-972.
30. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173-1181.
31. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288(19):2421-2431. (Pubitemid 35340538)
32. Jaar BG, Khatib R, Plantinga L, Boulware LE, Powe NR. Principles of screening for chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(2):601-609.
33. Kwong YT, Stevens LA, Selvin E, et al. Imprecision of urinary iothalamate clearance as a goldstandard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis. 2011;56(1):39-49.